3Quigley HA,Broman AT.The number of people with glaucoma worldwide in 2010 and 2020[J].Br J Ophthalmol,2006,90(3):262-267.
4Mallion JM,Schmitt D.Patient compliance in the treatment of arterial hypertension[J].J Hypertension,2001,19(12):2281-2283.
5Asrani S,Zeimer R,Wilensky J,et al.Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma[J].J Glaucoma,2000,9(2):134-142.
6Bron A,Baudouin C,Denis P,et al.Satisfaction and compliance of ocular hypertensive and glaucoma patients topically treated with a combination therapy[J].J Fr Ophtalmol,2008,31(7):659-665.
7Boger WP.Shortterm"escape"and longterm "drift":the dissipation effects of the beta adrenergic blocking agents[J].Surv Ophthalmol,1983,28(Suppl):235-242.
8Krieg A, Langenbruch G A. Susceptibility of arthropod species to Bacillus thuringiensis. Microbial Control of Pest and Diseases 1970-1980[M]. London: Academic Press, 1981. 837-896
9Krieg A, Hugeer A M, Schnetter W, et al. Bacillus thuringiensis var. san Diego strain M-7 is identical to B. thuringiensis subsp. tenebrionis strain BI256-82, which was previously isolated in Germany and is pathogenic to beetles[J]. J Appl Entomology, 198
10Bradfish G A. Nematocidal Bacillus thuringiensis toxins: opportunities in an animal health and plant protection[J]. Mycogen San Diego, 1992, CA92121:8-36
